Preexisting Adenovirus Seropositivity Is Not Associated With Increased HIV-1 Acquisition in Three HIV-1 Vaccine Efficacy Trials

Viral vectors as vaccine platforms: deployment in sight

(2011) Christine S Rollier et al.   CURRENT OPINION IN IMMUNOLOGY

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

(2011) Dan H. Barouch et al.   VACCINE

Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case–control study

(2010) Marcel E Curlin et al.   AIDS

Novel adenovirus vector-based vaccines for HIV-1

(2010) Dan H Barouch   Current Opinion in HIV and AIDS

Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine

(2010) Glenda Gray et al.   Current Opinion in HIV and AIDS

Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans

(2009) Kara L O'Brien et al.   NATURE MEDICINE

Baseline Ad5 serostatus does not predict Ad5 HIV vaccine–induced expansion of adenovirus-specific CD4+ T cells

(2009) Natalie A Hutnick et al.   NATURE MEDICINE

Failure of the Merck HIV vaccine: an uncertain step forward

(2008) Merlin L Robb   LANCET

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis

(2008) M Juliana McElrath et al.   LANCET

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

(2008) Susan P Buchbinder et al.   LANCET